FibroGen, Inc.’s FG-3019 Granted U.S. Orphan Drug Designation for the Treatment of Patients With Idiopathic Pulmonary Fibrosis

SAN FRANCISCO--(BUSINESS WIRE)--FibroGen, Inc., today announced that FG-3019, the Company’s human monoclonal antibody against connective tissue growth factor (CTGF), has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF).